Reuters logo
7 months ago
BRIEF-Pfizer says Phase 4 PLATO study did not meet its primary endpoint
December 14, 2016 / 9:57 PM / 7 months ago

BRIEF-Pfizer says Phase 4 PLATO study did not meet its primary endpoint

1 Min Read

Dec 14 (Reuters) - Pfizer Inc

* "Will continue to analyze these data to better understand results with goal of further helping these patients"

* Trial did not meet its primary endpoint

* "We are committed to continuing to explore clinical potential of XTANDI across disease continuum"

* Pfizer and Astellas announce top-line results from phase 4 PLATO trial of XTANDI (enzalutamide) capsules in patients with metastatic castration-resistant prostate cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below